TB-500 (Thymosin Beta-4): Complete Guide to Benefits, Dosing, and Research (2026)

TB-500 is one of the most widely used peptides in the recovery and performance space — and for good reason. A synthetic fragment of Thymosin Beta-4, a protein present in virtually every cell in the human body, TB-500 promotes tissue repair, reduces inflammation, accelerates wound healing, and supports new blood vessel formation. Often called the "universal healing peptide," it has earned a devoted following among athletes, biohackers, and researchers. This guide covers everything you need to know: the science, the dosing, the famous Wolverine Stack with BPC-157, and the current state of the research.

What Is TB-500? TB-500 vs. Thymosin Beta-4

Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino-acid peptide found in high concentrations in blood platelets, wound fluid, and most tissues. It plays a critical role in cell migration, angiogenesis (new blood vessel formation), and regulation of actin — the protein that gives cells their structural scaffolding.

TB-500 is not identical to Thymosin Beta-4. It is a synthetic analogue derived from the actin-binding domain of Tβ4, specifically amino acids 17–23. This shorter fragment (LKKTETQ) is believed to retain most of Tβ4's healing bioactivity while being easier and less expensive to synthesize. TB-500 also has much greater water solubility than the full protein, which improves bioavailability after subcutaneous injection.

Research from 2026 suggests that TB-500's wound-healing activity may partly stem from a metabolite called Ac-LKKTE, rather than the parent compound alone — an area of active investigation.

Mechanism of Action: How TB-500 Works

1. Actin Regulation

TB-500's primary mechanism involves binding to G-actin (monomeric actin), sequestering it and modulating its polymerization into F-actin filaments. By regulating the actin cytoskeleton, TB-500 enables rapid cell migration and proliferation — both essential steps in tissue repair and wound closure.

2. Anti-Inflammatory Signaling

TB-500 suppresses NF-κB-mediated inflammatory signaling, reducing pro-inflammatory cytokines and chemokines while upregulating anti-inflammatory mediators. In models of sepsis and organ inflammation, Thymosin Beta-4 has consistently demonstrated potent anti-inflammatory effects.

3. Angiogenesis

TB-500 promotes the formation of new blood vessels, ensuring damaged tissues receive adequate oxygen, nutrients, and immune cells for efficient repair. This angiogenic activity is especially relevant for healing chronic or poorly-vascularized injuries.

4. Stem Cell Mobilization

Emerging research indicates TB-500 promotes mobilization of endogenous stem cells from bone marrow to sites of injury, amplifying tissue regeneration beyond what local cell migration alone can achieve.

Reported Benefits

• Accelerated injury recovery: Musculoskeletal injuries — tendons, ligaments, muscles — are the most commonly cited use case in research communities.
• Reduced inflammation: Systemic anti-inflammatory effects that complement localized healing.
• Improved flexibility: Several users report increased soft tissue extensibility during cycles, possibly from improved collagen remodeling.
• Cardiac tissue repair: Animal studies show Tβ4 promotes repair of damaged heart tissue after myocardial infarction. It is the only peptide to have reached clinical trials for this indication (see Research section).
• Hair growth: Topical and systemic Tβ4 have shown hair follicle stimulation in animal models and limited human observations.
• Neuroprotection: Preclinical data suggests Tβ4 may protect and regenerate neural tissue, relevant to traumatic brain injury models.

TB-500 Dosing Protocol

Research protocols consistently use a two-phase structure: a loading phase to rapidly achieve therapeutic tissue saturation, followed by a lower-dose maintenance phase.

Total weekly loading dose ranges from 4–5 mg/week. After the loading phase, 2.5 mg/week is sufficient to maintain therapeutic levels. Typical research cycles run 8–12 weeks total. TB-500 has a long plasma half-life of approximately 7–10 days, which is why weekly dosing is sufficient during maintenance — unlike peptides such as BPC-157 that require daily administration.

Note: TB-500 is a research peptide. These dosing figures come from the research community and are not FDA-approved protocols. Consult a licensed physician before use.

How to Reconstitute and Inject TB-500

Reconstitution

• Remove the vial from the refrigerator 5–10 minutes before use and allow to warm to room temperature.
• Wipe the rubber stopper with a 70% isopropyl alcohol swab and allow to air dry.
• To reconstitute a 10 mg vial, draw 3.0 mL of bacteriostatic water — this yields a concentration of approximately 3.33 mg/mL.
• Insert the needle at the edge of the stopper and inject the water slowly down the interior glass wall — never directly onto the powder.
• Gently rotate the vial between your palms until fully dissolved. Do not shake or vortex. TB-500 is sensitive to mechanical degradation.

Injection

• Use a 28–31 gauge, 0.5-inch insulin syringe.
• Preferred injection sites: abdomen, outer thigh, or flank — rotate sites to prevent irritation.
• Pinch the skin and insert the needle at a 45-degree angle into the subcutaneous (fatty) layer.
• Inject slowly and steadily. Remove the needle and apply gentle pressure.

Storage

Unreconstituted lyophilized TB-500 can be stored at room temperature for short periods but should be refrigerated (2–8°C) for long-term storage. Once reconstituted in bacteriostatic water, it must be refrigerated and used within 28–30 days. Do not freeze reconstituted peptide.

The Wolverine Stack: TB-500 + BPC-157

The most widely discussed peptide stack for healing and recovery combines TB-500 with BPC-157 — nicknamed the "Wolverine Stack" in research and biohacking communities. These two peptides target overlapping but distinct healing pathways, producing synergistic effects neither achieves alone.

BPC-157 delivers the localized repair signal — particularly powerful for tendon, ligament, and gut injuries. TB-500 provides the systemic mobilization response, recruiting stem cells and reducing body-wide inflammation. Together, they cover the full spectrum of tissue repair. Important: never mix them in the same vial. Prepare each separately to maintain stability and dosing precision.

A typical Wolverine Stack protocol involves BPC-157 daily injections (near the injury site or subcutaneously) combined with TB-500 twice-weekly subcutaneous injections, run for 8–12 weeks.

Safety Profile and Side Effects

TB-500 has an exceptionally wide safety margin based on available data. Phase I testing of Thymosin Beta-4 showed that IV doses up to 1,260 mg daily for 14 days caused no serious adverse effects in healthy adults — approximately 250–600 times higher than typical subcutaneous research doses.

Reported side effects in research use are generally mild:

• Head rush / lightheadedness: Commonly reported immediately post-injection, typically brief and self-resolving.
• Fatigue: Some users report transient fatigue in the first few days of a loading phase.
• Injection site reactions: Redness, mild swelling — minimized by rotating injection sites and using proper technique.
• Theoretical cancer concern: Like all angiogenic peptides, TB-500 carries a theoretical risk of promoting tumor growth by stimulating new blood vessel formation. No clinical evidence confirms this risk in healthy individuals, but it is a standard precaution — those with active cancer or strong family history should avoid angiogenic peptides.

TB-500 does not appear to affect the hypothalamic-pituitary axis, hormone levels, or liver enzymes at research doses — distinguishing it favorably from many performance-enhancing compounds.

Research and Clinical Evidence

Wound Healing (Preclinical — Strong Evidence)

Topical and systemic Thymosin Beta-4 increased wound re-epithelialization by 42% at 4 days and 61% at 7 days versus saline controls in rat full-thickness wound models. Two Phase 2 clinical trials for chronic venous stasis ulcers and pressure ulcers showed Tβ4 accelerated healing by nearly one month in responding patients.

Corneal Healing

RegeneRx's topical Tβ4 formulation (RGN-259) has completed clinical trials for neurotrophic keratopathy and dry eye syndrome, showing accelerated corneal wound healing and reduced inflammation. This is one of the most clinically advanced Tβ4 applications.

Cardiac Repair

Thymosin Beta-4 demonstrated cardiac tissue repair and improved cardiac function after myocardial infarction in multiple animal models. This led to RegeneRx's Phase 2 trial (NCT01311518) — the most advanced cardiac peptide therapy application to date.

TB-500 Fragment Specifically

The TB-500 fragment itself (amino acids 17–23) has no completed human clinical trials. Evidence for its efficacy in humans is extrapolated from full-length Thymosin Beta-4 research and animal studies. This is an important distinction: the preclinical evidence is strong, but direct human trial data for the synthetic fragment is absent.

Legal and Regulatory Status

• FDA (USA): Not approved for human use. Classified as a research chemical for laboratory use only.
• WADA: Not explicitly listed on the 2024–2026 Prohibited List as a distinct compound, though it may fall under broad peptide hormone categories. Athletes subject to drug testing should verify with their governing body.
• Australia (TGA): Thymosin Beta-4 and its fragments are Schedule 4 (prescription only) substances. Unauthorized possession carries penalties.
• UK: Not licensed as a medicine. Legal to possess for personal research in limited quantities but illegal to sell for human use.
• EU: Unregulated as a research chemical in most member states, but sales for human use are prohibited.

Conclusion

TB-500 stands out in the peptide landscape for its combination of broad healing effects, favorable safety data, and practical long-half-life dosing schedule. The preclinical evidence for Thymosin Beta-4 — across wound healing, cardiac repair, corneal healing, and neuroprotection — is among the most robust of any research peptide. The clinical human trials, while limited to specific medical conditions and the full-length protein rather than the TB-500 fragment specifically, are genuinely promising.

For researchers focused on tissue repair and recovery, the Wolverine Stack of TB-500 + BPC-157 represents the most studied and widely-used peptide combination in this space. The complementary mechanisms — systemic mobilization from TB-500, localized repair from BPC-157 — provide a rational scientific basis for the stack.

As with all research peptides, TB-500 should be approached with an understanding of its research-only status, the importance of sourcing from reputable suppliers with third-party testing, and the absence of FDA-approved dosing protocols. The evidence base is growing steadily, and TB-500 remains one of the most compelling peptides in the current research landscape.

For educational purposes only. TB-500 is not FDA-approved for human use. Nothing in this article constitutes medical advice. Consult a licensed physician before using any peptide or research compound.